FAX Capital Corp. Sells 230,800 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of BioSyent stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total value of C$2,566,496.00.

BioSyent Stock Performance

CVE RX opened at C$11.52 on Wednesday. The company has a market capitalization of C$133.52 million, a PE ratio of 19.20 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. BioSyent Inc. has a 52-week low of C$8.24 and a 52-week high of C$11.74. The company has a 50-day simple moving average of C$11.06 and a 200 day simple moving average of C$10.29.

BioSyent (CVE:RX) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The company had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. On average, research analysts predict that BioSyent Inc. will post 0.6944444 EPS for the current year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.